854PDPazopanib (p) or sorafenib (s) + radium-223 (rad) in metastatic renal cell carcinoma (mrcc) with bone metastases (bm). (18th September 2017) - Bossé, D.; McKay, R.R.; Gray, K.P.; Michaelson, M.D.; Sleeper, C.; Walsh, M.; Krajewski, K.M.; Jacene, H.; Bellmunt, J.; Pomerantz, M.M.; Harshman, L.C.; Choueiri, T.K.